- Diagnostic Différentiel
Drug Information for EPOPROSTENOL (GeneraMedix Inc ): DESCRIPTION
- INDICATIONS AND USAGE
- DOSAGE AND ADMINISTRATION
- DOSAGE FORMS AND STRENGTHS
- DRUG INTERACTIONS
- PATIENT COUNSELING INFORMATION
- Diseases/Conditions Related to EPOPROSTENOL (GeneraMedix Inc )
- Liens externes liés à EPOPROSTENOL (GeneraMedix Inc )
Epoprostenol for Injection is a sterile sodium salt formulated for intravenous (IV) administration. Each vial of Epoprostenol for Injection contains epoprostenol sodium equivalent to 1.5 mg (1,500,000 ng) epoprostenol, 50 mg arginine, and 50 mg mannitol. Sodium hydroxide is added to adjust pH.
Epoprostenol (PGI2, PGX, prostacyclin), a metabolite of arachidonic acid, is a naturally occurring prostaglandin with potent vasodilatory activity and inhibitory activity of platelet aggregation.
Epoprostenol is (5 Z,9a,11a,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid. Epoprostenol sodium has a molecular weight of 374.45 and a molecular formula of C20H31NaO5. The structural formula is:
Epoprostenol for Injection is a white to off-white lyophilized material that may be translucent. It is reconstituted with Sterile Water for Injection, USP, or Sodium Chloride 0.9% Injection, USP.
The reconstituted solution of Epoprostenol for Injection has a pH of >11.0 and is increasingly unstable at a lower pH.
- Drug Information Provided by National Library of Medicine (NLM).